FDA Inspection
Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation – FDA Inspection, Jun 25, 2025
Record Details
This FDA Inspection record concerns Novartis Pharmaceuticals Corporation, with an inspection on June 25, 2025, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · d76eeb82-f498-4fa6-9c50-25c0625a0d59
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1276202
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
Other FDA inspections of Novartis Pharmaceuticals Corporation
30| Date | Classification | Office | Project area |
|---|---|---|---|
| June 24, 2026 | Not classified | New Jersey District Office | |
| March 3, 2025 | Not classified | New Jersey District Office | |
| November 19, 2024 | Not classified | New Jersey District Office | |
| August 29, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 27, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Novartis Pharmaceuticals Corporation
- FDA Inspection 1328008 - 2026-06-24
- FDA Inspection 1263198 - 2025-03-03
- FDA Inspection 1257911 - 2024-11-19
- FDA Inspection 1248433 - 2024-08-29
- FDA Inspection 1230105 - 2024-06-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.